<DOC>
	<DOCNO>NCT00003915</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Androgens stimulate growth prostate cancer cell . Hormone therapy use bicalutamide leuprolide may fight prostate cancer reduce production androgen . PURPOSE : Phase II trial study effectiveness chemotherapy consist docetaxel estramustine plus hormone therapy treat patient previously undergone radiation therapy surgical removal prostate stage I prostate cancer .</brief_summary>
	<brief_title>Chemotherapy Hormone Therapy Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility administer docetaxel plus estramustine combination androgen deprivation therapy patient PSA elevation follow radiotherapy radical prostatectomy early prostate cancer . - Evaluate regimen term PSA response rate , response duration , time future therapeutic intervention patient population . - Evaluate testosterone , free testosterone , sex hormone bind globulin relation treatment regimen patient . OUTLINE : Patients receive oral estramustine three time day day 1-5 docetaxel IV 1 hour day 2 . Treatment repeat every 3 week 4 course . Patients receive oral bicalutamide daily begin week 12 leuprolide intramuscularly every 3 month begin week 13 . Treatment continue 15 month . Patients follow every 3 month 2 year , every 4 month 1 year , every 6 month thereafter disease progression and/or subsequently death . Information collect subsequent prostate cancer treatment , time nature first evidence metastatic prostate cancer , date cause death . PROJECTED ACCRUAL : Approximately 55 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate No metastases No measurable evaluable disease 2 consecutively rise PSA level least 2 week apart , despite prior radical prostatectomy radiotherapy ( external beam implant ) PSA rise twice nadir value post radiotherapy PATIENT CHARACTERISTICS : Age : Not specify Performance status : 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great upper limit normal ( ULN ) Must meet 1 follow criterion : SGOT and/or SGPT great 2.5 time ULN AND alkaline phosphatase great ULN Alkaline phosphatase great 4.0 time ULN AND SGOT and/or SGPT great ULN SGOT SGPT great 1.5 time ULN AND alkaline phosphatase great 2.5 time ULN Renal : Not specify Cardiovascular : At least 6 month since prior myocardial infarction , angina , New York Heart Association class III IV heart disease No active thrombophlebitis At least 6 month since prior thromboembolic event include deep vein thrombosis cerebrovascular accident Other : No malignancy within past 5 year except curatively treat basal cell skin cancer No active infection No significant neuropathy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior estramustine suramin Endocrine therapy : At least 6 month since prior neoadjuvant adjuvant hormonal therapy great 6 month duration No concurrent corticosteroid Radiotherapy : Salvage radiotherapy post prostatectomy allow Surgery : See Disease Characteristics</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
</DOC>